94 related articles for article (PubMed ID: 9516972)
1. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.
Børresen-Dale AL; Lothe RA; Meling GI; Hainaut P; Rognum TO; Skovlund E
Clin Cancer Res; 1998 Jan; 4(1):203-10. PubMed ID: 9516972
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
Russo A; Migliavacca M; Zanna I; Valerio MR; Latteri MA; Grassi N; Pantuso G; Salerno S; Dardanoni G; Albanese I; La Farina M; Tomasino RM; Gebbia N; Bazan V
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1322-31. PubMed ID: 12433709
[TBL] [Abstract][Full Text] [Related]
3. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
4. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
[TBL] [Abstract][Full Text] [Related]
5. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
6. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
7. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
8. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
10. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
11. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
14. p53 point mutation and survival in colorectal cancer patients.
Goh HS; Yao J; Smith DR
Cancer Res; 1995 Nov; 55(22):5217-21. PubMed ID: 7585578
[TBL] [Abstract][Full Text] [Related]
15. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
16. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
17. Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease.
Garcia J; Duran A; Tabernero MD; Garcia Plaza A; Flores Corral T; Najera ML; Gomez-Alonso A; Orfao A
Cytometry B Clin Cytom; 2003 Jan; 51(1):14-20. PubMed ID: 12500293
[TBL] [Abstract][Full Text] [Related]
18. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
[TBL] [Abstract][Full Text] [Related]
19. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
20. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
